Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-05-09 Board/Management Inform…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of two new independent directors to the company's board. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about events or information. The content focuses on management/board changes and does not contain financial data, earnings, or detailed reports. The document length is 6247 characters, which is sufficient for a full announcement but it is clearly an announcement of board appointments rather than a report or filing of financial results. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-05-09 English
Annual Secretarial Compliance Report for the year ended March 31, 2024.
Regulatory Filings
2024-05-08 English
Audio recording of the Earnings Call - Q4 FY24.
Call Transcript Classification · 70% confidence The document is a letter addressed to stock exchanges informing them about the hosting of the audio recording of the Earnings Call for Q4 FY24. It references SEBI regulations related to disclosure requirements and provides a web link to the audio recording. The document does not contain the transcript or financial data itself, but rather announces the availability of the earnings call recording. The document length is short (1655 characters), and it is clearly an announcement rather than the full transcript or report. Therefore, it fits best under the category of Call Transcript (CT) since it relates to an earnings call, but since it only announces the audio recording and does not provide the transcript, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general disclosure announcement. However, given the specific nature of the announcement about the earnings call audio recording, the best fit is Call Transcript (CT) with moderate confidence, as it is directly related to the earnings call content.
2024-05-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing them about the hosting of the audio recording of the Earnings Call for Q4 FY24 on the company's website. It references the earnings call but does not contain any financial data or transcript itself. The document length is only 1641 characters, which is very short and fits the pattern of an announcement rather than the full earnings call transcript or financial report. According to the rules, announcements about reports or recordings being available are classified as Regulatory Filings (RNS) because it is a notification and not the report or transcript itself.
2024-05-07 English
Investor Presentation - Q4 FY24
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation - Q4 FY24' and is addressed to stock exchanges, indicating it is a formal disclosure. It contains detailed financial metrics, quarterly performance data, business highlights, market share information, and strategic initiatives for the fourth quarter of fiscal year 2024. The content includes forward-looking statements, sales and EBITDA figures, market performance, product pipeline, and compliance updates. The length is substantial (15,000 characters), and the document is a presentation format rather than a full financial report or earnings release. It is not an announcement of a report but the actual presentation material. Therefore, the document fits the definition of an Investor Presentation (IP).
2024-05-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation - Q4 FY24' and is addressed to stock exchanges, indicating it is a formal communication to investors. It contains detailed financial metrics, quarterly performance data, business highlights, market growth, pipeline information, and strategic initiatives for the fourth quarter of fiscal year 2024. The content includes forward-looking statements, financial snapshots, sales mix, and operational highlights typical of an investor presentation. There is no indication that this is a full annual or quarterly report, audit report, or earnings release summary. The document is not a brief announcement or a certification but a detailed presentation aimed at investors. Therefore, the document fits the category of an Investor Presentation (IP).
2024-05-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.